ArticleJournal of the International AIDS Society2022
Weight gain during the dolutegravir transition in the African Cohort Study.
Article in Journal of the International AIDS Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results.The Pediatric infectious disease journal · 2025Trial
- Integrated PrEP and STI Services for Transgender Women in Uganda: Qualitative Findings from a Randomized Trial.AIDS and behavior · 2025Trial
- Trial
- Predictors of Liver Steatosis Progression Among People Living With HIV in Low- and Middle-Income Countries: A Multicentre Longitudinal Study.Journal of the International AIDS Society · 2026Article
- Factors associated with viral suppression and antiretroviral therapy adherence among adolescents and young adults living with HIV in the African Cohort Study.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Clinical Outcomes of Tenofovir, Lamivudine, and Dolutegravir in Treatment-Naïve versus Treatment-Experienced HIV Patients: A Single-Center Retrospective Cohort Study in Indonesia.Infection & chemotherapy · 2026Article
- Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system.HIV medicine · 2026Article
- Article
- Examining the potential of mobile money-based health insurance for people living with HIV and hypertension or diabetes in Uganda.Frontiers in health services · 2026Article
- Incidence and Predictors of Hyperglycemia Among Adults Receiving Dolutegravir-Based Antiretroviral Therapy at Mbarara Regional Referral Hospital HIV Clinic, Uganda: A Retrospective Cohort Study.HIV/AIDS (Auckland, N.Z.) · 2026Article
- Longitudinal Weight Gain Trajectories After Initiation of Dolutegravir-Based Antiretroviral Therapy: A Retrospective Cohort Study.AIDS research and treatment · 2026Article
- Virological outcomes and treatment retention in North Vietnam amidst transition to social insurance-based HIV services and dolutegravir-based regimens.Scientific reports · 2025Article
- Prevalence and Correlates of Hyperglycemia Among People Living With HIV and TB on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe: A Cross-Sectional Study.Health science reports · 2025Article
- Quality-of-life changes six months after the programmatic switch from nevirapine to dolutegravir-based ART in stable PLWH: a prospective cohort study in Indonesia.Scientific reports · 2025Article
- Perceptions of body size and non-communicable disease risk among people with HIV in Nairobi, Kenya: an explanatory mixed-methods study.BMJ global health · 2025Article
- Maternal Phenotype, Infant Size and Breast Milk Composition in Women Living With HIV.Maternal & child nutrition · 2025Article
- Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Body weight changes in people with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania.AIDS (London, England) · 2025Observational
- The Transformative Impact of the African Cohort Study (AFRICOS) Toward Reaching HIV 95-95-95 Goals in Sub-Saharan Africa.The American journal of tropical medicine and hygiene · 2025Article
- Gaps in hypertension and diabetes treatment among people living with and without HIV: Findings from a prospective cohort study in Kenya, Nigeria, Tanzania, and Uganda, 2013-2023.PLOS global public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDolutegravir (DTG) has become a preferred component of first-line antiretroviral therapy (ART) in many settings but may be associated with excess weight gain. We evaluated changes in weight and body mass index (BMI) after switch to single-tablet tenofovir/lamivudine/dolutegravir (TLD) by people living with HIV (PLWH) in four African countries.
methodsThe African Cohort Study (AFRICOS) prospectively follows adults with and without HIV in Kenya, Uganda, Tanzania and Nigeria. Demographics, ART regimen, weight, BMI and waist-to-hip ratio were collected every 6 months. Multivariable Cox proportional hazards modelling was used to estimate hazard ratios and 95% confidence intervals (CIs) for factors associated with developing a BMI ≥25 kg/m
resultsFrom 23 January 2013 to 1 December 2020, 2950 PLWH were enrolled in AFRICOS and 1474 transitioned to TLD. In adjusted models, PLWH on TLD had 1.77 times the hazard of developing a high BMI (95% CI: 1.22-2.55) compared to PLWH on non-TLD ART. Examining change in weight among all PLWH on ART, participants on TLD gained an average of 0.68 kg (95% CI: 0.32-1.04) more than PLWH on other regimens after adjusting for duration on ART, sex, age, study site and CD4 nadir. Among participants who switched to TLD, the average change in weight prior to TLD switch was 0.35 kg/year (95% CI: 0.25-0.46) and average change in weight was 1.46 kg/year (95% CI: 1.18-1.75) in the year following transition to TLD after adjustment for confounders.
conclusionsElevated BMI and weight gain among PLWH on TLD are concerning safety signals. Implications for the development of metabolic comorbidities should be monitored, particularly if annual weight gain persists during continued follow-up after transitioning to TLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.